XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
Clinical Trial
USA Patient Registry Software Market Outlook to 2028, Featuring IQVIA, Optum (UnitedHealth Group), Phytel, Dacima Software, FIGmd, Syapse and Pharos Innovations – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "USA Patient Registry Software Market Outlook to 2028" report has been added to ResearchAndMarkets.com's offering. The United States...
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
PharmAla now first company to supply both MDMA and Psilocybin into the Australian MarketVANCOUVER, British Columbia, March 18, 2024 (GLOBE...
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey...
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene...
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,...
Aruna Bio to Participate in Upcoming Investor Conferences
BOSTON and ATHENS, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for...
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported...
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
Tribe Public Webinar with Indaptus Therapeutics Tribe Public Webinar with Indaptus Therapeutics “Fully Engaging The Human Immune System To Cure...
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing...
Unique Treatment for BPH, Chronic Prostatitis, Back Pain and Kidney Stones Was Unveiled at Arab Health 2024 by Ariana Adjani
* Efficacy, safety, and cost-effectiveness of Thermobalancing therapy and Dr Allen's Devices were showcased at the Arab Health Exhibition, the...
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis...
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.
The certification has the potential to open access to Islamic markets globally, expanding potential markets for Scilex’s innovative FDA approved...
Gain Therapeutics to Present at Public Ventures Discovery Day
Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President...
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement
PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue...
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
(This release corrects the release that was posted earlier on March 15, 2024 to update the Consolidated Balance Sheets)Conference call...
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN, MA / ACCESSWIRE / March 15, 2024...
Monogram Orthopaedics Reports Full Year 2023 Financial Results
510(k) Submission with FDA On Track for Second Half of 2024Shipped mBôs Surgical Robot System to First International CustomerIntroduced mVision...